ADXS-PSA is currently in pre-clinical development for the treatment of prostate cancer.
ADXS-PSA is an immunotherapy that is designed to target the PSA antigen associated with prostate cancer. By incorporating PSA into the Advaxis live, attenuated vector, Advaxis intends to deliver the PSA antigen, fused to the powerful immunostimulant LLO, directly inside antigen presenting cells that are capable of driving a cellular immune response to PSA expressing cells. The Advaxis approach is also designed to inhibit the Treg and MDSC cells that promote immunologic tolerance of the prostate cancer cells of the tumor.
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer. Prostate cancer is the second leading cause of cancer death in men, behind only lung cancer. One man in six will get prostate cancer during his lifetime, and one man in 36 will die of this disease. For additional information about prostate cancer, please visit: http://www.cancer.org/.